Table 2.

IMDC-related characteristics in patients treated with vedolizumab and infliximab alone (N=156)

Characteristic	Vedolizumab n=62	Infliximab n=94	P value
Median length of ICI treatment, days (IQR), n=156	73 (28–247)	70 (28–151)	0.846
Median time from ICI initiation-IMDC onset, days (IQR), n=156	104 (53–212)	96 (33–188)	0.065
No of ICI treatments before IMDC, mean (SD)	7 (8)	7 (6)	0.235
Diarrhea grade, no (%)			0.583
1–2	20 (32)	33 (35)
3–4	42 (68)	61 (65)
Colitis grade, no (%)			0.246
1–2	30 (48)	57 (61)
3–4	32 (52)	37 (39)
Median duration of initial IMDC symptoms, days (IQR), n=156	56 (27–80)	50 (31–69)	0.054
Endoscopy evaluation, no (%)	60 (96)	65 (69)	<0.001
Endoscopic presentation, no (%)			0.265
Mucosal ulceration	17 (28)	19 (29)
Non-ulcerative inflammation	32 (54)	37 (57)
Normal	11 (18)	9 (14)
Histology features–no (%)			0.105
Acute active colitis	12 (20)	24 (37)
Chronic active colitis	35 (58)	31 (48)
Microscopic colitis	13 (22)	10 (15)
IV steroids, no (%)	36 (58)	58 (62)	0.237
Median duration of steroids for initial IMDC, days (IQR), n=156	35 (27–43)	51 (41–68)	<0.001
No of steroid tapering attempts prior to SIT use, median (IQR), n=156	1 (1–3)	2 (2–3)	0.016
Median duration from IMDC to first dose of SIT- days (IQR), n=156	11 (9–48)	23 (19–37)	<0.001
No of SIT doses (%)			<0.001
1–2	21 (34)	77 (82)
≥3	41 (66)	17 (18)
Doses of SIT, mean (SD)	3 (2)	2 (1)	<0.001
Median duration from first dose of SIT to symptom remission or improvement to grade 1, days (IQR), n=138	18 (10–40)	13 (8–29)	0.012
Hospitalization, no (%)	40 (65)	67 (71)	0.367
Median duration of hospitalization, days (IQR), n=107	10 (5–15)	14 (8–19.8)	0.043
Multiple hospitalizations, no (%)	10 (16)	26 (28)	0.005
Clinical remission, no (%)	55 (89)	83 (88)	0.785
Recurrent IMDC, no. (%)	8 (14)	27 (29)	0.007
Immunosuppressant-associated infection, no (%)	12 (19)	23 (25)	0.184

ICI, immune checkpoint inhibitor; IMDC, immune-mediated diarrhea and colitis; IV, intravenous; SIT, selective immunosuppressive therapy.